Login to Your Account

CV Therapeutics' Tecadenoson Phase III Data Reported At AHA

By Kim Coghill

Thursday, November 21, 2002
At the 75th American Heart Association's Scientific Sessions in Chicago, CV Therapeutics Inc. presented data from a Phase III trial of a drug that exceeded the company's expectations in its ability to convert an abnormally rapid heart rhythm back to normal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription